Stem-Cell Gene Therapy for Sickle Cell Advances Toward Clinical Trials

  • Photo: Courtesy of Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
    Human red blood cells made from bone-marrow stem cells of a patient with sickle-cell disease. The red blood cells with BetaAS3 anti-sickling vector show the normal round shape, while those that were not corrected are sickle shaped. Photo: Courtesy of Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research

    Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have successfully established the foundation for using hematopoietic (blood-producing) stem cells from the bone marrow of patients with sickle-cell disease to treat the illness. The study was led by Donald Kohn, MD, professor of pediatrics and of microbiology, immunology and molecular genetics.

     

    Sickle-cell disease causes the body to produce misshapen red blood cells that form like the crescent-shaped blade of a sickle, which hinders blood flow and deprives the body’s organs of oxygen. Dr. Kohn introduced an anti-sickling gene into the hematopoietic stem cells to capitalize on the self-renewing potential of stem cells and create a continual source of healthy red blood cells that do not sickle. The breakthrough gene-therapy technique for sickle-cell disease is scheduled to begin clinical trials early next year.

     

    Dr. Kohn’s autologous gene-therapy approach is a revolutionary alternative to current sickle-cell disease treatments, which include transplanting patients with donor hematopoietic stem cells. Such transplants offer a potential cure for sickle-cell disease, but due to the serious risks of rejection, only a small number of patients have undergone this procedure, and it is usually restricted to children with severe symptoms.

     

    Dr. Kohn and colleagues found that in the laboratory, the hematopoietic stem cells produced new non-sickled blood cells at a rate sufficient for significant clinical improvement for patients. The new blood cells survive longer than sickled cells, which also could improve treatment outcomes.

     

    More than 90,000 patients in the U.S. have been diagnosed with sickle-cell disease. It is caused by an inherited mutation in the beta-globin gene that makes red blood cells change from their normal shape, which is round and pliable, into a rigid, sickle-shaped cell. Normal red blood cells are able to pass easily through the tiniest blood vessels, carrying oxygen to organs throughout the body. But due to their rigid structure, sickled blood cells get stuck in the small capillaries.

     

    “ß-globin Gene Transfer to Human Bone Marrow for Sickle Cell Disease,” Journal of Clinical Investigation, July 1, 2013

    From Around the Web...
    DAY THREE We heard from four incredibly wise and informative doctors on Saturday morning. 9 am The...
    Photo by Randall Cordero
    1. You can do it on your lunch break. Even though it works you hard, it does not leave you spent...
    Originally published in the Fall 2015 issue of Robb Report Health & Wellness as “Cognitive...
    Foreo Issa electric toothbrush: $199 Foreo has delivered a new toothbrush aimed at improving on...
    << Back top “80 Amazing Holiday Gifts.” The Level by FluidStance: $289–$429  “I’ve been on my...
    For runners looking to step up their game, Sensoria Fitness Smart Socks has them covered....
    Innovative, inspiring, and intuitive, the Ralph Lauren PoloTech smart shirt is everything you...
    Safe cycling is all about riding smart, and with the Livall Bling Helmet, using one’s head has...
    It is a perilous time to be sick. Medical error kills 400,000 Americans a year, making it the third...
    Two days ago the FDA approved Addyi, a new drug meant to boost the libido in women. While some see...